# BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

> **NCT03093168** · PHASE1 · UNKNOWN · sponsor: **The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine** · enrollment: 10 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Anti-BCMA CAR-T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03093168
- **Lead sponsor:** The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-15
- **Primary completion:** 2019-09
- **Final completion:** 2020-02
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2019-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093168, "BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03093168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*